Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Long-term Follow-Up Study to Evaluate the Safety and Tolerability of Gene Therapy With EXG102-031 in Participants With Neovascular Age-related Macular Degeneration

NCT06817343 is registered in ClinicalTrials.gov with Exegenesis Bio as lead sponsor.

NCT NCT06817343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06817343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Long-term Follow-Up Study to Evaluate the Safety and Tolerability of Gene Therapy With EXG102-031 in Participants With Neovascular Age-related Macular Degeneration
Lead sponsor
Exegenesis Bio
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 10, 2024
Completion date
February 28, 2029
Enrollment
12 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular (wet) age-related macular degeneration (amd), neovascular age-related macular degeneration (namd)